Evidence map›Paper›PMID 37213182›Full record

ArticleExperimental and clinical psychopharmacology2024

Novel methods for the remote investigation of emerging substances: Application to kratom.

Kirsten E Smith, Jeffrey D Feldman, Kelly E Dunn, Christopher R McCurdy, Oliver Grundmann, Albert Garcia-Romeu, Leigh V Panlilio, Jeffrey M Rogers, Abhisheak Sharma, Salma Pont-Fernandez and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Experimental and clinical psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Kirsten E SmithReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program.ORCID 0000-0002-9278-1830
Jeffrey D FeldmanReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program.ORCID 0000-0001-8906-6601
Kelly E DunnDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
Christopher R McCurdyDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida.
Oliver GrundmannDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida.
Albert Garcia-RomeuDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.ORCID 0000-0003-2182-1644
Leigh V PanlilioReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program.
Jeffrey M RogersJoint Doctoral Program in Clinical Psychology, San Diego State University/University of California San Diego.ORCID 0000-0001-8621-8948
Abhisheak SharmaDepartment of Pharmaceutics, College of Pharmacy, University of Florida.ORCID 0000-0003-0553-4039
Salma Pont-FernandezReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program.
Marina KheyfetsReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program.
David H EpsteinReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program.
National Institute on Drug Abuse · USUniversity of Florida · USJohns Hopkins University · USSan Diego State University · US

Funding

Real-Time Assessment of Drug Use, Along with Mental States and EnvironmentsZIADA000499 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI EPSTEIN, DAVID · 2009 to 2025
$19.9M
Opioid use disorders: UF Pharmacy medications discovery and developmentUH3DA048353 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2021 to 2023
$4.5M
Opioid use disorders: UF Pharmacy medications discovery and developmentUG3DA048353 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2019 to 2020
$3.6M
Kratom alkaloids: in vitro and in vivo pharmacological mechanismsR01DA047855 · NIDA · UNIVERSITY OF FLORIDA · PI MCCURDY, CHRISTOPHER R, MCMAHON, LANCE R. · 2019 to 2023
$3.6M
Real-world momentary assessment of kratom use and laboratory-based observed cessation accompanied by product assays: Toward an interdisciplinary characterization of kratom use and pharmacologyR00DA055571 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SMITH, KIRSTEN · 2024 to 2025
$498k
NIDA NIH HHS K99 DA055571NIDA NIH HHS R00 DA055571NIDA NIH HHS R01 DA047855NIDA NIH HHS UG3 DA048353NIDA NIH HHS UH3 DA048353
6 · The paper itself

Abstract

The botanical product commonly called "kratom" is still relatively novel to the United States. Like other natural products marketed as supplements, kratom is highly variable, both in terms of the alkaloids naturally occurring in kratom leaves and in terms of processing and formulation. Kratom products sold in the United States are not well-characterized, nor are daily use patterns among regular users. Surveys and case reports have comprised most of the literature on kratom use among humans. To advance our understanding of real-world kratom use, we developed a protocol for the remote study of regular kratom-using adults in the United States. Our study had three aspects implemented in one pool of participants nationwide: an in-depth online survey, 15 days of ecological momentary assessment (EMA) via smartphone app, and the collection and assay of the kratom products used by participants during EMA. Here, we describe these methods, which can be used to investigate myriad drugs or supplements. Recruiting, screening, and data collection occurred between July 20, 2022 and October 18, 2022. During this time, we demonstrated that these methods, while challenging from a logistical and staffing standpoint, are feasible and can produce high-quality data. The study achieved high rates of enrollment, compliance, and completion. Substances that are emerging or novel, but still largely legal, can be productively studied via nationwide EMA combined with assays of shipped product samples from participants. We discuss challenges and lessons learned so other investigators can adapt these methods. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

Indexed as

MitragynaAdultEcological Momentary AssessmentHumansSurveys and QuestionnairesUnited States

Identifiers

PMID37213182
PMCPMC10663387
OpenAlexW4377221041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.